Ramucirumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/29999742/
No information is available on the clinical use of ramucirumab during breastfeeding. Because ramucirumab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in...
Relevance: No information is available on the clinical use of ramucirumab during breastfeeding. Because ramucirumab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in milk is likely to be very low.
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35461050/
Real-world data show NGS-based approaches to be superior to non-NGS. Uptake of molecular testing and the corresponding targeted treatments was less than expected based on guidelines and even more so...
Conclusion: Real-world data show NGS-based approaches to be superior to non-NGS. Uptake of molecular testing and the corresponding targeted treatments was less than expected based on guidelines and even more so for trials, off-label use and compassionate use, indicating less than optimal access to rational treatment options.
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35429394/
doi: 10.1093/oncolo/oyac051. Online ahead of print. 1 Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. 2 Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. 3 Department...
Conclusion: We defined predictors and prognostic-economic impact of nivolumab in etd patients.
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
Source : https://www.sciencedirect.com/science/article/pii/S193652332200078X?via=ihub
Patients' perspectives are at the center of value-based oncology care. * Patient reported outcomes (PROs) guide clinical and regulatory decisions. * PRO instruments do not capture immune-related adverse events in...
Conclusion: Nivolumab alleviated symptom burden and improved health status of patients in the registrational clinical trials of advanced NSCLC. However, incapability of the included PRO instruments to measure immune-related AEs, differences in timing of PRO evaluation between treatment groups, incomplete patient participation at all time...
AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35429904/
Non-small cell lung cancer (NSCLC) ranks first among cancer death worldwide. Despite efficacy and safety priority, targeted therapy only benefits ∼30% patients, leading to the unchanged survival rates for whole...
Conclusion: These newly acquired data not only establish the specific role for AKR1C1 in metabolic reprogramming, but also hint to the possibility that AKR1C1 may be a new therapeutic target for NSCLC treatment.